NASDAQ:SEEL Seelos Therapeutics (SEEL) Stock Price, News & Analysis $0.44 -0.03 (-6.38%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.43▼$0.5050-Day Range$0.44▼$1.7552-Week Range$0.43▼$398.40Volume295,712 shsAverage Volume1.33 million shsMarket Capitalization$954,800.00P/E RatioN/ADividend YieldN/APrice Target$360.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Seelos Therapeutics alerts: Email Address Seelos Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside81,718.2% Upside$360.00 Price TargetShort InterestBearish10.89% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 stars 3.2 Analyst's Opinion Consensus RatingSeelos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSeelos Therapeutics has received no research coverage in the past 90 days.Read more about Seelos Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.89% of the float of Seelos Therapeutics has been sold short.Short Interest Ratio / Days to CoverSeelos Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Seelos Therapeutics has recently increased by 116.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSeelos Therapeutics does not currently pay a dividend.Dividend GrowthSeelos Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SEEL. Previous Next 3.0 News and Social Media Coverage News SentimentSeelos Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Seelos Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for SEEL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Seelos Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seelos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Seelos Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 23.37% of the stock of Seelos Therapeutics is held by institutions.Read more about Seelos Therapeutics' insider trading history. Previous Next N/A Earnings and Valuation Read more about Seelos Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.I have uncovered a bombshell that changes everything… and threatens everything. About Seelos Therapeutics Stock (NASDAQ:SEEL)Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.Read More SEEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SEEL Stock News HeadlinesJuly 8, 2024 | investorplace.com3 Next-Gen Drug Stocks Exploring Psychedelic FrontiersMay 17, 2024 | msn.comSeelos Therapeutics announces pricing of about $1M registered direct offering & concurrent private placementJuly 27, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.May 16, 2024 | prnewswire.comSeelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMay 14, 2024 | investorplace.comSEEL Stock Earnings: Seelos Therapeutics Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | prnewswire.comSeelos Therapeutics Announces 1-for-8 Reverse Stock SplitMay 4, 2024 | seekingalpha.comSEEL Seelos Therapeutics, Inc.May 3, 2024 | marketwatch.comSeelos Therapeutics to Cut Workforce by 33%, Reduce Working HoursJuly 27, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.April 29, 2024 | markets.businessinsider.comSeelos Therapeutics Appoints Richard Pascoe As Chairman Of The BoardApril 29, 2024 | prnewswire.comSeelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and CollaborationsMarch 22, 2024 | investorplace.comSEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023March 20, 2024 | markets.businessinsider.comOptimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial ResultsMarch 19, 2024 | markets.businessinsider.comSeelos: Phase 2/3 HEALEY ALS Trial Fails To Meet Statistical Significance In EndpointsMarch 19, 2024 | marketwatch.comSeelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary EndpointsMarch 19, 2024 | markets.businessinsider.comNasdaq Down 100 Points; US Housing Starts Surge In FebruaryMarch 19, 2024 | msn.comCNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's WhyMarch 19, 2024 | reuters.comSeelos says ALS treatment fails in mid-stage studySee More Headlines Receive SEEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/27/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SEEL CUSIPN/A CIK1017491 Webwww.seelostherapeutics.com Phone(646) 293-2100Fax858-436-8155Employees20Year Founded2016Price Target and Rating Average Stock Price Target$360.00 High Stock Price Target$480.00 Low Stock Price Target$240.00 Potential Upside/Downside+81,718.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,880,000.00 Net Margins-1,373.61% Pretax Margin-1,373.61% Return on EquityN/A Return on Assets-740.27% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.10 Sales & Book Value Annual Sales$2.20 million Price / Sales0.43 Cash FlowN/A Price / Cash FlowN/A Book Value($27.37) per share Price / Book-0.02Miscellaneous Outstanding Shares2,170,000Free Float2,056,000Market Cap$954,800.00 OptionableNo Data Beta1.89 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Raj Mehra J.D. (Age 64)Ph.D., CEO, Founder, President & Director Comp: $599.53kMr. Michael J. Golembiewski (Age 52)Chief Financial Officer Comp: $388.2kMr. Anthony MarcianoChief Communications OfficerGopal Krishna Ph.D.Head of Manufacturing & Technical OperationsTim Whitaker M.D.Chief Medical OfficerMs. Karen FusaroSenior VP & Head of Clinical OperationsMore ExecutivesKey CompetitorsChina PharmaNYSE:CPHIEvoke PharmaNASDAQ:EVOKClever LeavesNASDAQ:CLVRGenprexNASDAQ:GNPXTrevenaNASDAQ:TRVNView All CompetitorsInstitutional OwnershipGendell Jeffrey LBought 317,351 shares on 5/15/2024Ownership: 2.583%View All Institutional Transactions SEEL Stock Analysis - Frequently Asked Questions How have SEEL shares performed this year? Seelos Therapeutics' stock was trading at $11.12 at the start of the year. Since then, SEEL shares have decreased by 96.0% and is now trading at $0.44. View the best growth stocks for 2024 here. How were Seelos Therapeutics' earnings last quarter? Seelos Therapeutics, Inc. (NASDAQ:SEEL) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($1.60) earnings per share (EPS) for the quarter. The business earned $0.58 million during the quarter. When did Seelos Therapeutics' stock split? Seelos Therapeutics's stock reverse split on the morning of Thursday, May 16th 2024. The 1-8 reverse split was announced on Tuesday, May 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Seelos Therapeutics? Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Seelos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX) and Co-Diagnostics (CODX). This page (NASDAQ:SEEL) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seelos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
